View in EDS HTML Full Text PDF Full Text

A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma.

Saved in:
Bibliographic Details
Title: A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma.
Authors: Dileo R; Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA, 15222, USA., Mewawalla P; Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA, 15222, USA., Babu K; Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA, 15222, USA., Yin Y; Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, USA., Strouse C; Division of Hematology, Oncology, and Blood and Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospital and Clinics, Iowa City, IA, USA., Chen E; Division of Hematology, Oncology, and Blood and Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospital and Clinics, Iowa City, IA, USA., Shaikh H; Division of Hematology, Oncology, and Blood and Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospital and Clinics, Iowa City, IA, USA., Davis JA; Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC, USA., Green KM; Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC, USA., Alkharabsheh O; University of South Alabama Mitchell Cancer Institute, Mobile, AL, USA., Rashid A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, MO, USA., Pokhrel B; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, MO, USA., Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, MO, USA., Abdallah AO; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, MO, USA., Hashmi H; Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC, USA. hashmih1@mskcc.org.; Myeloma & Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hashmih1@mskcc.org.
Source: Blood cancer journal [Blood Cancer J] 2025 Mar 10; Vol. 15 (1), pp. 34. Date of Electronic Publication: 2025 Mar 10.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40064854
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Dileo+R%22">Dileo R</searchLink>; Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA, 15222, USA.<br /><searchLink fieldCode="AU" term="%22Mewawalla+P%22">Mewawalla P</searchLink>; Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA, 15222, USA.<br /><searchLink fieldCode="AU" term="%22Babu+K%22">Babu K</searchLink>; Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA, 15222, USA.<br /><searchLink fieldCode="AU" term="%22Yin+Y%22">Yin Y</searchLink>; Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Strouse+C%22">Strouse C</searchLink>; Division of Hematology, Oncology, and Blood and Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospital and Clinics, Iowa City, IA, USA.<br /><searchLink fieldCode="AU" term="%22Chen+E%22">Chen E</searchLink>; Division of Hematology, Oncology, and Blood and Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospital and Clinics, Iowa City, IA, USA.<br /><searchLink fieldCode="AU" term="%22Shaikh+H%22">Shaikh H</searchLink>; Division of Hematology, Oncology, and Blood and Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospital and Clinics, Iowa City, IA, USA.<br /><searchLink fieldCode="AU" term="%22Davis+JA%22">Davis JA</searchLink>; Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC, USA.<br /><searchLink fieldCode="AU" term="%22Green+KM%22">Green KM</searchLink>; Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC, USA.<br /><searchLink fieldCode="AU" term="%22Alkharabsheh+O%22">Alkharabsheh O</searchLink>; University of South Alabama Mitchell Cancer Institute, Mobile, AL, USA.<br /><searchLink fieldCode="AU" term="%22Rashid+A%22">Rashid A</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, MO, USA.<br /><searchLink fieldCode="AU" term="%22Pokhrel+B%22">Pokhrel B</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, MO, USA.<br /><searchLink fieldCode="AU" term="%22Ahmed+N%22">Ahmed N</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, MO, USA.<br /><searchLink fieldCode="AU" term="%22Abdallah+AO%22">Abdallah AO</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, MO, USA.<br /><searchLink fieldCode="AU" term="%22Hashmi+H%22">Hashmi H</searchLink>; Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC, USA. hashmih1@mskcc.org.; Myeloma & Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hashmih1@mskcc.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2025 Mar 10; Vol. 15 (1), pp. 34. <i>Date of Electronic Publication: </i>2025 Mar 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40064854
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41408-025-01226-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 34
    Titles:
      – TitleFull: A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dileo R
      – PersonEntity:
          Name:
            NameFull: Mewawalla P
      – PersonEntity:
          Name:
            NameFull: Babu K
      – PersonEntity:
          Name:
            NameFull: Yin Y
      – PersonEntity:
          Name:
            NameFull: Strouse C
      – PersonEntity:
          Name:
            NameFull: Chen E
      – PersonEntity:
          Name:
            NameFull: Shaikh H
      – PersonEntity:
          Name:
            NameFull: Davis JA
      – PersonEntity:
          Name:
            NameFull: Green KM
      – PersonEntity:
          Name:
            NameFull: Alkharabsheh O
      – PersonEntity:
          Name:
            NameFull: Rashid A
      – PersonEntity:
          Name:
            NameFull: Pokhrel B
      – PersonEntity:
          Name:
            NameFull: Ahmed N
      – PersonEntity:
          Name:
            NameFull: Abdallah AO
      – PersonEntity:
          Name:
            NameFull: Hashmi H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 03
              Text: 2025 Mar 10
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2044-5385
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Blood cancer journal
              Type: main
ResultId 1